Worth reading
81Important
Scored from 3 of 5 sectionsDirection
Mixed performance
Direction inferred from the company’s description.Scale
—
Displayed only when the document provides numerical figures.Wording
Avoiding a definitive answer
How definitive the wording is.Revised forecast
Fiscal year ended June 2025 · Full yearNet Sales—→5,050million
—
Operating profit—→-400million
—
Ordinary income—→-400million
—
Profit attributable to owners of the parent—→-450million
—
The bar length represents the relative magnitude of change, based on the item that changed the most in this document.
Reason for the revision
健康補助食品では売価変更と広告費・販促費の適正化、ヘルスケアサポートでは契約健康保険組合数の増加、生体評価システムでは受注伸長を見込む一方、化粧品では中国国内の景況感不透明と組織スリム化に伴う一時費用、機能性素材開発ではフェムテック事業領域への研究開発費増加を見込む。
Details and amount of extraordinary loss
固定資産除却損1,315千円、固定資産売却損134千円、投資有価証券評価損9,272千円、減損損失38,124千円。特別損失合計48,846千円。
Previous-period results売上高 5,158百万円、営業損失 △610百万円、経常損失 △565百万円、親会社株主に帰属する当期純損失 △662百万円
Consolidated / non-consolidatedConsolidated
| Item | Details |
|---|---|
| Net Sales | Not disclosed → ¥5,050 million |
| Operating profit | Not disclosed → ¥-400 million |
| Ordinary income | Not disclosed → ¥-400 million |
| Profit attributable to owners of the parent | Not disclosed → ¥-450 million |
| Fiscal Period Covered | Fiscal year ended June 2025 |
| Period Covered | Full year |
| Previous-period results | 売上高 5,158百万円、営業損失 △610百万円、経常損失 △565百万円、親会社株主に帰属する当期純損失 △662百万円 |
| Reason for the revision | 健康補助食品では売価変更と広告費・販促費の適正化、ヘルスケアサポートでは契約健康保険組合数の増加、生体評価システムでは受注伸長を見込む一方、化粧品では中国国内の景況感不透明と組織スリム化に伴う一時費用、機能性素材開発ではフェムテック事業領域への研究開発費増加を見込む。 |
| Details and amount of extraordinary loss | 固定資産除却損1,315千円、固定資産売却損134千円、投資有価証券評価損9,272千円、減損損失38,124千円。特別損失合計48,846千円。 |
| Consolidated / non-consolidated | Consolidated |
Items this document does not state (3)
Net income per sharePublication date of previous forecastDividend forecast revision
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.生体評価システムでは医薬臨床研究支援事業の廃止などにより売上が減少し、化粧品では中国市場向け商品の不買運動、取引開始の遅れ、競争激化が影響した。健康補助食品では原材料価格の高騰と新商品の広告宣伝費の先行投資、機能性素材開発では原料販売数量の伸び悩みがあった。次期は、売価変更、広告・販促費の適正化、受注拡大、OEM販売拡大、研究開発投資、組織のスリム化などを前提としている。
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.